Skip to main content
Back
RYTM logo

Rhythm Pharmaceuticals, Inc.

Data quality: 100%
RYTM
NASDAQ Healthcare Biotechnology
$82.59
▼ $2.06 (-2.43%)
Mkt Cap: 5.64B
Day Range
$80.70 $83.75
52-Week Range
$45.91 $122.20
Volume
771,417
50D / 200D Avg
$99.01 / $96.18
Prev Close
$84.65

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E -28.7 0.3
P/B 40.6 2.9
ROE % -129.5 3.7
Net Margin % -103.6 3.8
Rev Growth 5Y % 178.5 10.0
D/E 1.8 0.2

Analyst Price Target

Hold
$140.18 +69.7%
Low: $125.00 High: $157.00
Forward EPS
-$3.08
Est. Revenue
290 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $12.09
$8.29 – $14.94
 1.9 B 3
FY2029 $7.49
$5.13 – $9.25
 1.4 B 3
FY2028 $3.08
$0.10 – $5.89
 900 M 9

Key Takeaways

Revenue grew 178.51% annually over 5 years — strong growth
Negative free cash flow of -116.63M
Revenue growth is decelerating — 1Y growth trails 5Y average by 132.68%
Capital efficient — spends only 0.50% of revenue on capex

Growth

Revenue Growth (5Y)
178.51%
Revenue (1Y)45.83%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-129.46%
ROIC-37.35%
Net Margin-103.57%
Op. Margin-101.19%

Safety

Debt / Equity
1.77
Current Ratio4.41
Interest Coverage-9.33

Valuation

P/E Ratio
-28.69
P/B Ratio40.55
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 45.83% Revenue Growth (3Y) 56.55%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 178.51% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 189.76M Net Income (TTM) -196.54M
ROE -129.46% ROA -40.84%
Gross Margin 89.73% Operating Margin -101.19%
Net Margin -103.57% Free Cash Flow (TTM) -116.63M
ROIC -37.35% FCF Growth (3Y) N/A
Safety
Debt / Equity 1.77 Current Ratio 4.41
Interest Coverage -9.33 Dividend Yield 0.00%
Valuation
P/E Ratio -28.69 P/B Ratio 40.55
P/S Ratio 29.72 PEG Ratio 1.25
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 5.64B Enterprise Value 5.83B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 189.76M 130.13M 77.43M 23.64M 3.15M
Net Income -196.54M -260.60M -184.68M -181.12M -69.61M
EPS (Diluted) -3.11 -4.34 -3.20 -3.51 -1.37
Gross Profit 170.27M 116.76M 68.13M 21.51M 2.56M
Operating Income -192.02M -265.50M -184.36M -179.16M -170.06M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 481.19M 392.27M 332.75M 382.48M 329.52M
Total Liabilities 342.13M 227.72M 162.99M 118.22M 45.37M
Shareholders' Equity 139.07M 164.55M 169.76M 264.26M 284.15M
Total Debt 246.47M 3.94M 1.26M 1.94M 2.55M
Cash & Equivalents 54.30M 89.14M 60.08M 127.68M 59.25M
Current Assets 466.92M 374.20M 308.27M 354.24M 308.39M
Current Liabilities 105.94M 115.52M 55.20M 39.81M 43.43M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#9 of 146
74

Recent Activity

Entered Full Throttle
Mar 24, 2026